Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.71 |
| ▸ | THRB | P10828 | 8/20 | 0.71 |
| ▸ | BLM | P54132 | 7/20 | 0.71 |
| ▸ | RECQL | P46063 | 6/20 | 0.71 |
| ▸ | TOP2A | P11388 | 5/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 4/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.71 |
| ▸ | FYN | P06241 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17404468 | 1.00 | MEN1 (0.71) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL17929837 | 0.95 | MEN1 (0.67) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL20456899 | 0.94 | S100A4 (0.63) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18351643 | 0.92 | MEN1 (0.60) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL17706678 | 0.92 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL30465123 | 0.91 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL10014019 | 0.91 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL17929849 | 0.91 | MEN1 (0.64) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL17929838 | 0.91 | MEN1 (0.70) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL9607884 | 0.91 | MEN1 (0.70) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105950690-A | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters | 阿特纳赞塔里斯有限公司 | 2016-09-21 | — | — | CN | disclosed |
| WO-2016116335-A1 | ENZYMATIC PROCESS FOR THE REGIOSELECTIVE MANUFACTURING OF N-FMOC-DOXORUBICIN-14-O-DICARBOXYLIC ACID MONO ESTERS | AETERNA ZENTARIS GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| US-20160208298-A1 | ENZYMATIC PROCESS FOR THE REGIOSELECTIVE MANUFACTURING OF N-FMOC-DOXORUBICIN-14-O-DICARBOXYLIC ACID MONO ESTERS | AETERNA ZENTARIS GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160208298-A1 | ENZYMATIC PROCESS FOR THE REGIOSELECTIVE MANUFACTURING OF N-FMOC-DOXORUBICIN-14-O-DICARBOXYLIC ACID MONO ESTERS | AETERNA ZENTARIS GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3045540-A1 | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters | Æterna Zentaris GmbH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-20150038429-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-20150038429-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-8828925-B2 | Etoposide and doxorubicin conjugates for drug delivery | ANGIOCHEM INC. (CA) | 2014-09-09 | — | — | US | disclosed |
| US-8828925-B2 | Etoposide and doxorubicin conjugates for drug delivery | ANGIOCHEM INC. (CA) | 2014-09-09 | — | — | US | disclosed |
| US-20120135914-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC. (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120135914-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC. (CA) | 2012-05-31 | — | — | US | disclosed |
| EP-0441218-A2 | Anthracycline-glycosyl prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates | BEHRINGWERKE Aktiengesellschaft (DE) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135914-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | GLS, AQP4, ABCB1 | MEN1 582/4885KMT2A 527/4885THRB 4818/4885 |
| US-20150038429-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | GLS, AQP4, ABCB1 | MEN1 582/4885KMT2A 527/4885THRB 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.